Neonatal multisystem inflammatory syndrome (MIS-N) associated with prenatal maternal SARS-CoV-2: a single-center experience Authors: Cansu Sivrikaya Yildirim, Hilal Ozkan, Kevser Ustun Elmas, Fatma Kocael, Salih Cagri Cakir, Solmaz Celebi, Mustafa Hacimustafaoglu, Fahrettin Uysal, Ozlem Mehtap Bostan, Nilgun Koksal Published: 2025 ABSTRACT AbstractObjectivesNeonatal Multisystem Inflammatory Syndrome (MIS-N) is believed to result either from the transplacental transfer of maternal SARS-CoV-2 antibodies or from a delayed hyperinflammatory response triggered by the neonate’s own immune reaction to SARS-CoV-2 infection. In this study we aim to explore the clinical presentation, laboratory findings, and current approaches to the diagnosis and management of MIS-N in neonates.Material and MethodA total of 15 infants with MIS-N followed in Bursa Uludag University Neonatal Intensive Care Unit between January 2022 and January 2023 were included in this retrospective study.ResultsEight mothers had a history of COVID-19 disease during pregnancy. All of neonates had cardiac involvement (supraventricular tachycardia, persistant sinusal bradycardia or AV block) and 10 infants had respiratory failure. All infants had elevated inflammatory biomarkers and received steroids or/and IVIG. Two infants died. ConclusionThe common presentation of MIS-N included cardiac aritmia and respiratory failure. Newborns with MIS-N may be at higher risk for adverse outcomes. Early diagnosis and treatment are important in these patients.Keywords: Neonate, Multisystem inflammatory syndrome, Anti SARS-CoV-2 antibodies, COVID-19 Introduction The emergence and global dissemination of Coronavirus Disease 2019 (COVID-19) has been accompanied by a growing number of reports describing multisystem inflammatory syndrome in children (MIS-C), a hyperinflammatory condition temporally associated with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection [1]. The exact pathogenesis of MIS-C is unknown. The most likely hypothesis is post-infective immune dysregulation [2]. Various studies have shown that maternal antibodies and inflammatory cytokines are transfered on to the fetus and these antibodies and cytokines can cause immune activation in the newborn baby [3, 4]. Recently, multisystem inflammatory syndrome in the newborn (MIS-N) has been defined. Although MIS-C diagnosis and treatment criteria have been defined there are only case series related to MIS-N [1, 4, 5]. MIS-N may present with different clinical findings, such as cardiac arrhythmia, shock, respiratory failure or sepsis. We present a case series of 15 neonates with multisystem involvement, hyperinflammatory syndrome and positive anti SARS-CoV-2 IgG antibodies, temporally related to maternal antenatal SARS-CoV-2 exposure. To our knowledge, this is the first serie of MIS-N presenting in the neonatal period in Turkey. Materials and methods This retrospective study was performed in Uludag University Neonatal Intensive Care Units (NICU) between January 2022 and January 2023. The study protocol was approved by the Ethics Committee of Uludag University, Faculty of Medicine. Written informed consent was obtained from the parents of all patients included in the study. Definition of MIS-N There is a clear definition of MIS-C in children as described by the World Health Organization (WHO) and Centers for Disease Control (CDC). But there is no agreed definition of MIS-N. We defined criteria of MIS-N according to Pawar et al.’s [4] study (Table 1). Table 1Inclusion criteria of neonatal multisystem inflammatory syndrome1. A neonate aged < 28 days at the time of presentation2. Laboratory or epidemiologic evidence of SARS-CoV-2 infection in the mother • Positive SARS-CoV-2 testing by RT-PCR, serology (IgG or IgM), or antigen during pregnancy • Symptoms consistent with SARS CoV-2 infection during pregnancy • COVID-19 exposure with confirmed SARS CoV-2 infection during pregnancy • Serological evidence (positive IgG specific to SARS CoV-2 but not IgM) in the neonate3. Clinical criteria • Severe illness necessitating hospitalization AND • Two or more organ systems affected [i.e., cardiac, renal, respiratory, hematologic, gastrointestinal, dermatologic, neurological, temperature instability (fever or hypothermia)] OR • Cardiac AV conduction abnormalities OR coronary dilation or aneurysms (without involvement of a second organ system)4. Laboratory evidence of inflammation • One or more of the following: an elevated CRP, ESR, fibrinogen, procalcitonin, D-dimer, ferritin, LDH, or IL-6; elevated neutrophils or reduced lymphocytes; low albumin5. No alternative diagnosis (such as birth asphyxia–cord pH < 7.0 and Apgar score < 3 at 5 min; viral or bacterial sepsis–confirmed blood culture; maternal lupus resulting in neonatal AV conduction abnormalities; presence of these findings indicating an alternate diagnosis excludes MIS-N).CRP C-reactive protein, LDH Lactate dehydrogenase, ESR Erythrocyte sedimentation rate, IL-6 ınterleukine-6 Inclusion criteria of neonatal multisystem inflammatory syndrome 2. Laboratory or epidemiologic evidence of SARS-CoV-2 infection in the mother • Positive SARS-CoV-2 testing by RT-PCR, serology (IgG or IgM), or antigen during pregnancy • Symptoms consistent with SARS CoV-2 infection during pregnancy • COVID-19 exposure with confirmed SARS CoV-2 infection during pregnancy • Serological evidence (positive IgG specific to SARS CoV-2 but not IgM) in the neonate 3. Clinical criteria • Severe illness necessitating hospitalization AND • Two or more organ systems affected [i.e., cardiac, renal, respiratory, hematologic, gastrointestinal, dermatologic, neurological, temperature instability (fever or hypothermia)] OR • Cardiac AV conduction abnormalities OR coronary dilation or aneurysms (without involvement of a second organ system) 4. Laboratory evidence of inflammation • One or more of the following: an elevated CRP, ESR, fibrinogen, procalcitonin, D-dimer, ferritin, LDH, or IL-6; elevated neutrophils or reduced lymphocytes; low albumin CRP C-reactive protein, LDH Lactate dehydrogenase, ESR Erythrocyte sedimentation rate, IL-6 ınterleukine-6 Laboratory tests SARS-CoV-2 antigens were tested using the real-time polymerase chain reaction (RTPCR) method in nasopharyngeal swabs. Euroimmun anti-SARS-Co-V2 ELISA Ig G and Colloidal Gold rapid test were used for detection of anti-SARS-CoV-2 Ig G in both maternal and neonatal serum samples. In all cases, the baseline investigations included complete blood count (CBC), C-reactive protein (CRP), procalcitonin (PCT), D-dimer, creatinine kinase (CK-MB), troponin (TropT), Pro B-type natriuretic peptide (proBNP), ferritin, lactate dehidrogenase (LDH) and coagulation profile. In cases with suspected cardiac involvement echocardiography (ECHO) was performed. Immunomodulator therapy (intravenous immunoglobulin, IVIG) was based on the guidelines and recommendations. Results The median of gestational age and birth weight were 38 week and 3295 g in all of patients. Of the 15 mothers 8 (53.3%) were symptomatic for COVID-19 during pregnancy, 7 (46.7%) were asymptomatic but serological positive for COVID-19. All of symptomatic mothers had febrile ilness and were in the second trimester. Six out of 15 mothers were not vaccinated before or during pregnancy. Clinical features Clinical characteristics of 15 neonates are shown in Table 2. Individual patient characteristics. Table 2Clinical CharacteristicsMaternal, [mean (min-max)]• Age31.4 (21–42)• Symptoms n (%) o Asymptomatic o Symptomatic8 (53.3)7 (46.7)• Gestatioanal week when positive or had exposure21.37 (18–26)• Cesarean delivery, n (%)10 (66.7)Neonatal, [mean (min-max)]• Gestational week37.8 (36–40)• Birth weight, (gr)3429 (2050–5970)• Postnatal age (day)3.4 (1–17)• Gender (Female/Male)9 (60)• Clinical findings n (%) o Cardiac o Respiratory o Hematologic/thrombosis o Gastrointestinal o Neurological o Cutaneous o Renal o Fever/temperature instability15 (100)10 (66.7)4 (26.7)3 (20)4 (26.7)1 (6.6)4 (26.7)1 (6.6)• Single system involvement (cardiac)4 (26,6)• Multipl system involvement11 (73,3)• Laboratory tests, [mean (min-max)] o CBC ■ WBC count (mm3) ■ Hemoglobine (gr/dl) ■ Platelet (mm3) o Inflamatory markers ■ C-reactive proteine (mg/L) ■ Procalcitonin (microgr/L) o Cardiac markers ■ Troponine ■ NT-Pro BNP ■ CK (IU/L) ■ CK-MB (microgr/L) o Others, [mean (min-max)] ■ Ferritin (microgr/L) ■ LDH (IU/L) ■ Albumin (gr/dL) ■ D-Dimer (microgr/L)20,495 (8690–47500)16.86 (9.40–21.5)268,253 (20000–518000)4.27 (2–19)4.99 (0.09–21.67)715.2 (9.40–6564)1604 (101.8–5000)996 (74-3029)75.23 (2.9–232)4399 (28 -29950)868.33 (369–2032)3.44 (2.1–5.1)7322 (363–47225)• Therapy n (%) o Steroids o IVIG o LMWH o Inotropes3 (20)14 (93.3)0 (0)4 (26.7)• Outcome, [mean (min-max)] o Mortality, n(%) o Duration day of hospitalization, [mean (min-max)]2 (13.3)17 (5–61) Clinical Characteristics • Symptoms n (%) o Asymptomatic o Symptomatic 8 (53.3) 7 (46.7) • Clinical findings n (%) o Cardiac o Respiratory o Hematologic/thrombosis o Gastrointestinal o Neurological o Cutaneous o Renal o Fever/temperature instability 15 (100) 10 (66.7) 4 (26.7) 3 (20) 4 (26.7) 1 (6.6) 4 (26.7) 1 (6.6) • Laboratory tests, [mean (min-max)] o CBC ■ WBC count (mm3) ■ Hemoglobine (gr/dl) ■ Platelet (mm3) o Inflamatory markers ■ C-reactive proteine (mg/L) ■ Procalcitonin (microgr/L) o Cardiac markers ■ Troponine ■ NT-Pro BNP ■ CK (IU/L) ■ CK-MB (microgr/L) o Others, [mean (min-max)] ■ Ferritin (microgr/L) ■ LDH (IU/L) ■ Albumin (gr/dL) ■ D-Dimer (microgr/L) 20,495 (8690–47500) 16.86 (9.40–21.5) 268,253 (20000–518000) 4.27 (2–19) 4.99 (0.09–21.67) 715.2 (9.40–6564) 1604 (101.8–5000) 996 (74-3029) 75.23 (2.9–232) 4399 (28 -29950) 868.33 (369–2032) 3.44 (2.1–5.1) 7322 (363–47225) • Therapy n (%) o Steroids o IVIG o LMWH o Inotropes 3 (20) 14 (93.3) 0 (0) 4 (26.7) • Outcome, [mean (min-max)] o Mortality, n(%) o Duration day of hospitalization, [mean (min-max)] 2 (13.3) 17 (5–61) are shown in Table 3. Cardiac and respiratory All of neonates had cardiac involvement (supraventricular tachycardia (n = 8), persistant sinusal bradycardia (n = 4), AV block (n = 1), wide QRS complex bradycardia (n = 1)) and 10 infants had respiratory failure. Three patients had cardiac arrest and shock. Ten patients needed invasive or non-invasive mechanical ventilation. Antiarrhythmic therapy was applied in seven patients with supraventricular tachycardia. All of newborns were sinus rhythm on discharge. Distribution of patients with cardiac involvement are shown in Table 4. Table 3Clinical Features n (%)CardiacArrhythmiaShock / cardiac dysfunction15 (100)15 (100)4 (26,6)RespiratoryRespiratory distress10 (66,6)HematologicalThrombocytopeniaDisseminated intravascular coagulation4 (26,6)2 (13,3)4 (26,6)RenalAcute renal failure4 (26,6)NeurologicalEncephalopathySeizure4 (26,6)4 (26,6)1 (6,6)GastrointestinalFeeding intolerance3 (20)3 (20)Cutaneous1 (6,6)Fever/temperature instabilityHypothermia1 (6,6) Clinical Features n (%) Cardiac Arrhythmia Shock / cardiac dysfunction 15 (100) 15 (100) 4 (26,6) Respiratory Respiratory distress Hematological Thrombocytopenia Disseminated intravascular coagulation 4 (26,6) 2 (13,3) 4 (26,6) Renal Acute renal failure Neurological Encephalopathy Seizure 4 (26,6) 4 (26,6) 1 (6,6) Gastrointestinal Feeding intolerance 3 (20) 3 (20) Fever/temperature instability Hypothermia Renal Four patients had acute renal failure and hemodiafiltration was applied to two of these patients. Hematological Four patients had hematological disorders that disseminated intravascular coagulation (DIC). Fresh frozen plasma was used for treatment. None of the patients had thrombosis. Neurogical Four newborns had encephalopathy. One of them did not cry immediately after birth, had an APGAR score of 5 at the 5th minute, and had a seizure on the second day (case 3). He was treated with anticonvulsant medication. Other newborns were 17, 7, 1 days old (Cases 1, 4 an 11) and had severe encephalopathy. Cutaneus Case 4 had hemorrhagic bullous lesions and on pathological examination, the epidermis had a necrotic appearance and there was leukocytoclastic inflammation. She was treated local medication (antibiotic and epithelial ointment). These lesions resolved within 3 weeks. Laboratory tests Anti-SARS-CoV-2 IgM antibodies were negative in all the neonates, and IgG antibodies were positive. All infants had elevated inflammatory biomarkers and the elevated biomarkers are shown in Table 5. Table 4Distribution of patients with cardiac involvement n (%)Supraventricular tachycardia8 (53,3)Wolf Parkinson White Sydrome1 (6,6)Persistent sinus bradycardia4 (26,6)Wide QRS bradycardia1 (6,6)First-degree atrioventricular block1 (6,6)Fetal tachycardia1 (6,6) Distribution of patients with cardiac involvement n (%) Treatment Fourteen infants were managed with supportive therapy and IVIG. Three patients were treated with methylprednisolone. While 13 out of 15 newborns were discharged, two neonates (case 5 and case 11) died due to multi-organ failure. Detailed clinical and laboratory information of 15 patients is shown in Table 6. Table 5Elevated inflammatory markers n (%)Ferritin12 (80)Procalcitonin6 (40)CRP5 (33,3)D dimer12 (80) Elevated inflammatory markers n (%) Table 6Clinical features, treatments, and outcomes with Neonatal Inflammatory Multisystem SyndromeAge at Presentation/ Sex/Weight/GestationMaternal COVID-19 StatusMaternal Serology (Ig G antibody)Neonatal SerologyLaboratory StudiesClinical FeaturesTreatmentOutcome1Day 17/ F3.6 kg39 weeksFebrile ilness 21 weeks before delivery, no PCR validation, no vaccinationIg G +Titer: 177 U/mLIg G +Titer:250 U/mLElevated PCT (19,41), ferritin (29950), D dimer (5551), troponin I (332.3), LDH (1675), INR (7.2), PT (100.2), aPTT (84), thrombocytopenia (123000)Cardiac arrest on day 17, severe respiratory distres, disseminated intravascular coagulation, shock (hypotension), supraventricular tachycardia, Echo – LV dysfunction, encephalopathy, acute renal failure, feeding intoleranceVentilation, cardiac support, antiarrhythmic treatment (esmolol, sotalol, flecainide), antibiotics, therapeutic hypothermia,IVIG (two intermittant doses, 1 gr/kg)Discharge on PN 39th daySinus rhytm on discharge2Day 2 / M3.4 kg39 weeksAsymptomatic, single dose of mRNA vaccine 21 weeks before deliveryIg G +Titer: 8798 U/mLIg G +Titer: 9677 U/mLElevated CRP (10), ferritin (273)Respiratory distres, persistant sinus bradycardiaVentilation, antibiotics, IVIG (single dose 1 gr/kg)Discharge on PN 16th daySinus rhytm on discharge3Day 1 / M4 kg40 weeksAsymptomatic, no vaccinationIg G +Titer: 50 U/mLIg G +Titer: 3120 U/mLElevated PCT (10,3), ferritin (466), D dimer (47225), troponin I (137), BNP (337), LDH (1530), INR (2.2), PT (23.8), aPTT (40.7), leukocytosis (31460)Respiratory distres, disseminated intravascular coagulation, seizure, sinus bradycardia, encephalopathyVentilation, antibioticsIVIG (two intermittant doses, 1 gr/kg), steroids (methylprednisolone, 2 mg/kg/d), anticonvulsantDischargeon PN 30th day4Day 7 / F3.3 kg39 weeksFebrile ilness 19 weeks before delivery, COVID-19 PCR positive, no vaccinationIg G +Titer:250 U/mLIg G +Titer :350 U/mLElevated ferritin (9067), D dimer (2951), troponin I (319), LDH (595), BNP (1678), INR (9.5), PT (120), aPTT (160), leukocytosis (33830)Cardiac arrest on day 7, severe respiratory distres, disseminated intravascular coagulation, shock (hypotension), acute renal failure, encephalopathy, wide QRS complex bradycardia, feeding intolerance, hypothermia, hemorrhagic bullous lesionsVentilation, cardiac support, therapeutic hypothermia, antibiotics, hemodiafiltration,IVIG (two intermittant doses, 1 gr/kg), steroidsDischargeon PN 60th day5Day 5 / F4 kg38 weeksAsymptomatic, two doses mRNA vaccine, last dose was 6 weeks before deliveryIg G +Titer: 1413 U/mLIg G +Titer: 1394 U/mLElevated CRP (11.1), PCT (21.67), ferritin (21995), D dimer (5604), troponin I, (3125), BNP (5000), LDH (2032), leukocytosis (47500), anemia (Hb:9.4)Severe respiratory distres, shock (hypotension), acute renal failure, 1st degree AV block, wide QRS complex, pulmonary hypertensionVentilation, cardiac support, antibiotics, hemodiafiltration,IVIG (two intermittant doses, 1 gr/kg), steroids (methylprednisolone, 2 mg/kg/d)Death on day 7 -multi-organ dysfuntion6Day 1 / M5.9 kg38 weeksFebrile ilness 18 weeks before delivery, no PCR validation, no vaccinationIg G +Titer: 6034 U/mLIg G +Titer: 9381 U/mLElevated CRP (19.1), D dimer (2128), LDH (757), BNP (879)Respiratory distres, supraventricular tachycardiaVentilation,antiarrhythmic treatment (esmolol, sotalol), antibiotics,IVIG (single dose 1 gr/kg)Discharge on PN 12th daySinus rhytm on discharge7Day 8/ M3200 gr38 weeksFebrile ilness 14 weeks before delivery, COVID PCR positive, two doses mRNA vaccine before pregnancyIg G +Titer: 2036 U/mLIg G +Titer: 2236 U/mLElevated D dimer (4828), ferritin (1044), BNP (1048)Respiratory distres, supraventricular tachycardiaVentilation, antibiotics, IVIG (single dose 1 gr/kg)Discharge on PN 18th day8Day 1/M3540 gr40 weeksFebrile ilness 17 weeks before delivery, COVID PCR positiveIg G +Titer : 15,619 U/mLIg G +Titer :15,440 U/mLElevated ferritin (487), D dimer (5575), LDH (828)Persistant sinus bradycardiaIVIG (single dose 1 gr/kg)Discharge on PN 10 th day9Day 1/M3480 gr36 weeksFebrile ilness 18 weeks before delivery, two doses mRNA vaccine before pregnancyIg G +Titer : 6652 U/mLIg G +Titer : 4996 U/mLNormalFetal tachycardia at 33th gestation week, tachycardia was not observed in the postnatal period, feeding intoleranceAntibioticsDischarge on PN 5 th day10Day 1 / F2050 gr36 weeksAsymptomatic, one dose mRNA vaccine before pregnancyIg G +Titer : 20,457 U/mLIg G +Titer : 22,805 U/mLElevated ferritin (522), D dimer (10360), BNP (273)Persistant sinus bradycardiaAntibiotics, IVIG (single dose 1 gr/kg)Discharge on PN 11 th day11Day 1 / F2735 gr36 weeksFebrile ilness 10weeks before delivery, no PCR validation, two doses mRNA vaccine before pregnancyIg G +Titer : 2050 U/mLIg G +Titer : 1745 U/mLElevated PCT (15.52), ferritin (601), D dimer (16711), troponin I (6564), BNP (5000), LDH (1947), INR (2,9), PT (29,5), aPTT (54), thrombocytopenia (20000)Severe respiratory distres, disseminated intravascular coagulation, shock (hypotension), supraventricular tachycardia resistant to medical treatment and requring ECMO, Echo – LV dysfunction, encephalopathy, acute renal failure, multipl organ failureVentilation, cardiac support, antiarrhythmic treatment (esmolol, flecainide, propranolol), antibiotics, ECMO,IVIG (two intermittant doses, 1 gr/kg), steroids (methylprednisolone, 2 mg/kg/d)Death on day 19 -multi-organ dysfuntion12Day 1 / F3230 gr37 weeksAsymptomatic, two doses mRNA vaccine before pregnancyIg G +Titer : 5199U/mLIg G +Titer : 6652 U/mLElevated ferritin (337), BNP (1564)Wolf Parkinson White Sydrome, supraventricular tachycardia compatible with sustained and non-sustanied atrioventricular reciprocating tachycardiaAntiarrhythmic treatment (propranolol, flecainide), IVIG (single dose 1 gr/kg)Discharge on PN 10 th day13Day 1 / F3780 gr38 weeksAsymptomatic, two doses mRNA vaccine, before pregnancyIg G +Titer : 12,480/mLIg G +Titer : 15,804 U/mLElevated D dimer (796), ferritin (530)Supraventricular tachycardiaAntiarrhythmic treatment (propranolol, flecainide), IVIG (single dose 1 gr/kg)Discharge on PN 10 th day14Day 3 / M2520 gr38 weeksAsymptomatic, two doses inactive vaccine, before pregnancyIg G +Titer : 10,313/mLIg G +Titer : 7011/mLElevated ferritin (328), D dimer (1598), LDH (532),Respiratory distres, supraventricular tachycardia, Echo – large VSD, large ASDAntiarrhythmic treatment (propranolol, captopril, furosemide), IVIG (single dose 1 gr/kg)Discharge on PN 33 th day15Day 1 / M3295 gr36 weeksFebrile ilness 14weeks before delivery, two doses mRNA vaccine before pregnancyIg G +Titer : 20,853/mLIg G +Titer : 13,730/mLNormalRespiratory distres, supraventricular tachycardiaAntiarrhythmic treatment (propranolol, flecainide), IVIG (single dose 1 gr/kg)Discharge on PN 7 th dayF Female, M Male, COVID-19 Corona virus disease 2019, PCR Polymerase chain reaction, Ig G Immunoglobulin G antibody. Normal ranges and units for lab values, PCT: 0–0.05 µg/L, CRP:0–10 mg/L, serum amiloid A: 0–8 mg/L, ferritin = 25–200 µg/L, D-Dimer 0–550 µg/L, BNP: 0-100 ng/L, LDH 290–775 U/L, INR:0-1.6, PT: 10–16 s, aPTT: 31–55 s, CK: mg/dL. PCT Procalcitonin, LDH Lactate dehydrogenase, INR International normalized ratio, PT Protrombin time, aPTT Activated partial thromboplastin time, LV left ventricule, IVIG Intravenous immunoglobulin, PN Postnatal, mRNA Messenger ribonucleic acid, CRP C-reactive protein, HIE Hypoxic ischemic encephalopathy, AV Atrioventricular, CK Creatinin kinase, VSD Ventricular septal defect, ASD Atrial septal defect Clinical features, treatments, and outcomes with Neonatal Inflammatory Multisystem Syndrome Day 17/ F 3.6 kg 39 weeks Ig G + Titer: 177 U/mL Ig G + Titer:250 U/mL Ventilation, cardiac support, antiarrhythmic treatment (esmolol, sotalol, flecainide), antibiotics, therapeutic hypothermia, IVIG (two intermittant doses, 1 gr/kg) Discharge on PN 39th day Sinus rhytm on discharge Day 2 / M 3.4 kg 39 weeks Ig G + Titer: 8798 U/mL Ig G + Titer: 9677 U/mL Discharge on PN 16th day Sinus rhytm on discharge Day 1 / M 4 kg 40 weeks Ig G + Titer: 50 U/mL Ig G + Titer: 3120 U/mL Ventilation, antibiotics IVIG (two intermittant doses, 1 gr/kg), steroids (methylprednisolone, 2 mg/kg/d), anticonvulsant Discharge on PN 30th day Day 7 / F 3.3 kg 39 weeks Ig G + Titer:250 U/mL Ig G + Titer :350 U/mL Ventilation, cardiac support, therapeutic hypothermia, antibiotics, hemodiafiltration, IVIG (two intermittant doses, 1 gr/kg), steroids Discharge on PN 60th day Day 5 / F 4 kg 38 weeks Ig G + Titer: 1413 U/mL Ig G + Titer: 1394 U/mL Ventilation, cardiac support, antibiotics, hemodiafiltration, IVIG (two intermittant doses, 1 gr/kg), steroids (methylprednisolone, 2 mg/kg/d) Day 1 / M 5.9 kg 38 weeks Ig G + Titer: 6034 U/mL Ig G + Titer: 9381 U/mL Ventilation, antiarrhythmic treatment (esmolol, sotalol), antibiotics, IVIG (single dose 1 gr/kg) Discharge on PN 12th day Sinus rhytm on discharge Day 8/ M 3200 gr 38 weeks Ig G + Titer: 2036 U/mL Ig G + Titer: 2236 U/mL Day 1/M 3540 gr 40 weeks Ig G + Titer : 15,619 U/mL Ig G + Titer :15,440 U/mL Day 1/M 3480 gr 36 weeks Ig G + Titer : 6652 U/mL Ig G + Titer : 4996 U/mL Day 1 / F 2050 gr 36 weeks Ig G + Titer : 20,457 U/mL Ig G + Titer : 22,805 U/mL Day 1 / F 2735 gr 36 weeks Ig G + Titer : 2050 U/mL Ig G + Titer : 1745 U/mL Ventilation, cardiac support, antiarrhythmic treatment (esmolol, flecainide, propranolol), antibiotics, ECMO, IVIG (two intermittant doses, 1 gr/kg), steroids (methylprednisolone, 2 mg/kg/d) Day 1 / F 3230 gr 37 weeks Ig G + Titer : 5199U/mL Ig G + Titer : 6652 U/mL Day 1 / F 3780 gr 38 weeks Ig G + Titer : 12,480/mL Ig G + Titer : 15,804 U/mL Day 3 / M 2520 gr 38 weeks Ig G + Titer : 10,313/mL Ig G + Titer : 7011/mL Day 1 / M 3295 gr 36 weeks Ig G + Titer : 20,853/mL Ig G + Titer : 13,730/mL F Female, M Male, COVID-19 Corona virus disease 2019, PCR Polymerase chain reaction, Ig G Immunoglobulin G antibody. Normal ranges and units for lab values, PCT: 0–0.05 µg/L, CRP:0–10 mg/L, serum amiloid A: 0–8 mg/L, ferritin = 25–200 µg/L, D-Dimer 0–550 µg/L, BNP: 0-100 ng/L, LDH 290–775 U/L, INR:0-1.6, PT: 10–16 s, aPTT: 31–55 s, CK: mg/dL. PCT Procalcitonin, LDH Lactate dehydrogenase, INR International normalized ratio, PT Protrombin time, aPTT Activated partial thromboplastin time, LV left ventricule, IVIG Intravenous immunoglobulin, PN Postnatal, mRNA Messenger ribonucleic acid, CRP C-reactive protein, HIE Hypoxic ischemic encephalopathy, AV Atrioventricular, CK Creatinin kinase, VSD Ventricular septal defect, ASD Atrial septal defect Discussion MIS-N is a clinical syndrome characterized by multisystem involvement and a hyperinflammatory state secondary to transient maternal antenatal SARS-CoV-2 infection in babies born to pregnant women with positive anti-SARS-CoV-2 IgG antibodies [4]. Diagnosis is based on clinical presentation and laboratory findings such as elevated inflammatory markers, thrombocytopenia, liver dysfunction, and coagulopathy [6]. Although the diagnostic criteria for MIS-C in childhood have been established by CDC, there is not yet consensus, even between the World Health Organization and CDC, on the diagnostic criteria for MIS-N [5]. The multisystem inflammatory response associated with SARS-CoV-2 is believed to occur through three distinct pathophysiological mechanisms and may lead to multisystem inflammatory syndrome in the neonatal period (MIS-N): (a) active infection of the neonate following maternal SARS-CoV-2 infection — a mechanism unique to neonates and distinct from the CDC definition of MIS-C; (b) neonatal extrapulmonary multisystem inflammation resulting from active SARS-CoV-2 infection; and (c) a delayed hyperinflammatory response triggered by early or late neonatal SARS-CoV-2 infection [7]. Furthermore, the immunological mechanisms are not yet fully understood. Although activation of monocytes and increase in proinflammatory cytokines and complement have been demonstrated in MIS -C, this immunologic mechanism has not been demonstrated in MIS -N because complement does not cross the placenta [8]. Therefore, this case series presents 15 newborns diagnosed MIS -N based on the revised CDC criteria using information from various case series and systematic reviews. MIS-N diagnostic criteria are listed in Table 1 [4, 7]. The first case was reported in August 2020 by Magboul et al. [6]. There are no case series from our country in the literature. The incidence of MIS -N was reported to be 0.1% in one review [9]. The incidence of MIS -N was 24.6% in the patients we observed in our department (Early MIS -N (within the first 72 h of life) is probably by transplacental transmission of maternal SARS-CoV-2 antibody. Late MIS -N (after 72 h of life)-presumably due to antibodies produced secondary to neonatal SARS-CoV-2 infection or transplacental transmission of maternal SARS-CoV-2 antibodies [10]. In our study, 11 patients were diagnosed with early MIS-N. It is believed that early MIS -N is caused by vertical transmission, whereas MIS -N in the late stage is caused by horizontal transmission. None of our patients diagnosed with early or late MIS -N had a COVID − 19 history of disease in their parents or caregivers. It can be presumed that MIS-N developed in our patients because of the vertical transition. In addition, the literature has revealed that maternal SARS-CoV-2 infection or exposure to COVID-19 can potentially cause multisystem inflammation in the early neonatal period. In our study, 8 mothers (53.3%) had COVID − 19 symptoms during pregnancy, and 7 mothers (37.5%) were asymptomatic but serologically positive for COVID-19. All symptomatic mothers had febrile illness and symptoms occurred in the second trimester. The serologic response in mother and neonate was confirmed by examination of serum Anti-SARS-CoV-2 Ig G from both mother and neonate. SARS-CoV-2 infection in neonates is asymptomatic in 40–45% [11]. Less than 15% of neonates develop moderate to severe symptoms of respiratory distress, lethargy, poor feeding, vomiting, diarrhea, and hemodynamic instability [12]. In a review of neonates diagnosed with MIS -N, the cardiovascular system [67%], was found to be most commonly affected, followed by the respiratory system [64%], fever [52%], central nervous system [22%], gastrointestinal system [11%], persistent pulmonary hypertension of the newborn (PPHN) [8%], skin involvement [4%] and hematological system [6%], respectively [9]. In our study, all patients had cardiac conduction abnormalities and/or arrhythmias. Involvement of the respiratory system was observed second most frequently. A case series found that maternal SARS-CoV-2 infection may be associated with multisystem inflammation in the neonatal period, as well as thrombosis and AV excitation conduction abnormalities [1]. Four patients presented only when cardiac involvement was present in our study; we did not have any patient with thrombosis. Two patients were found to have cardiac arrhythmias in the fetal period (case 9, case 11). Fetal tachycardia was detected at 33 weeks’ gestation in the first patient and at 22 weeks’ gestation in the second patient and they were followed up at another health center during the prenatal period without treatment. There is no evidence in the literature that the findings of MIS-N begin in the prenatal period. However, one case report describes two cases of fetal supraventricular tachycardia after administration of Pfizer-BioNTech’s vaccine COVID − 19 during pregnancy [13]. To confirm the diagnosis MIS-N, additional inflammatory markers such as CRP, procalcitonin, and ferritin should be elevated, we found a large number of positive markers such as ferritin, CRP, and procalcitonin [4]. Altough, a systematic review reported that D-dimer elevation was most common and ferritin elevation was observed in only 45% of patients; in our study, the most frequently elevated inflammatory markers were ferritin and D-dimer. IVIG, steroids, anticoagulants, and anticytokines may be preferred as specific treatment options, with the first treatment step consisting of supportive therapies (such as respiratory support, perfusion, antibiotic therapy) [4, 7, 14]. The most commonly used specific treatment was IVIG (93.3%) among patients who participated in our study, and steroids (26%) were the second most commonly used. A review in the literature reported that 4.2% of patients developed multiple organ failure and the mortality rate was 9–11% [9, 14]. In our study, 2 patients died due to multiorgan failure, and the mortality rate was 13%, similar to the literature. Both dead patients were late preterm infants with a history of 36 weeks’ gestation. This study has several limitations. It is retrospective, and the small sample size may limit the generalizability of the findings. Conclusion Inadequate recognition of MIS-N can lead to under-reporting of cases and under-diagnosis. The most common systemic findings in MIS-N are cardiac arrhythmias and respiratory failure. Neonates diagnosed with MIS-N have a high mortality and morbidity rate, and the prognosis of these infants can be poor. MIS-N neonates in whom two or more systems are affected, infection should be considered if SARS-CoV2 antibodies and elevated inflammatory markers are present. In these patients, early diagnosis and an appropriate treatment regimen are important. Acknowledgements No acknowledgements. Financial status The study has no financial source. Authors’ contributions This study was performed in collaboration with all the authors. OH and KN designed the study. SYC, UEK, KF, CCS, CS, HM, UF, BOM collected and analyzed the data. OH and SYC drafted the manuscript. OH, KN, CCS and SYC reviewed and edited the draft. All authors approved the final version of the manuscript. Funding No funding. Data availability The authors confirm that the data supporting the findings of this study are available within the article and as additional supporting files. Declerations Ethics approval and consent to participate Ethical approval for the study was obtained before the commencement of the study from the Ethics Committee of Uludag University, Faculty of Medicine. The study was conducted in accordance with the Declaration of Helsinki. Written informed consent was obtained from the parents of all patients included in the study. Consent for publication Not applicable. Competing interests The authors declare no competing interests. Footnotes Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations. References Associated Data Data Availability Statement The authors confirm that the data supporting the findings of this study are available within the article and as additional supporting files.